F-star Therapeutics, Inc.
FSTX · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $21 | $11 | $28 | $0 |
| % Growth | 88.1% | -60.3% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $21 | $11 | $28 | $0 |
| % Margin | 100% | 100% | 100% | – |
| R&D Expenses | $29 | $14 | $31 | $20 |
| G&A Expenses | $23 | $20 | $15 | $9 |
| SG&A Expenses | $23 | $20 | $15 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $52 | $34 | $47 | $28 |
| Operating Income | -$31 | -$22 | -$22 | -$28 |
| % Margin | -145.1% | -198.9% | -79.4% | – |
| Other Income/Exp. Net | -$1 | -$3 | -$2 | $6 |
| Pre-Tax Income | -$32 | -$26 | -$24 | -$23 |
| Tax Expense | -$0 | -$0 | -$1 | $0 |
| Net Income | -$31 | -$26 | -$23 | -$23 |
| % Margin | -147.8% | -227.6% | -81.3% | – |
| EPS | -1.88 | -2.82 | -2.54 | -1.6 |
| % Growth | 33.3% | -11% | -58.7% | – |
| EPS Diluted | -1.88 | -2.82 | -2.54 | -1.6 |
| Weighted Avg Shares Out | 17 | 9 | 9 | 15 |
| Weighted Avg Shares Out Dil | 17 | 9 | 9 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $9 | $0 |
| EBITDA | -$29 | -$21 | -$13 | -$28 |
| % Margin | -139% | -188.7% | -47.1% | – |